ABSTRACT: New food sources are needed to bridge the gap between vitamin D intake and recommended intake. We assessed the bioavailability and efficacy of vitamin D in an 8 week dose-response study of bread made with vitamin D 2 -rich yeast compared to vitamin D 3 in growing, vitamin D-deficient rats. Plasma 25-hydroxyvitamin D (25OHD) levels increased in a curvilinear, dosedependent manner with both forms of vitamin D, but rats fed vitamin D 2 -rich yeast achieved lower levels than rats fed vitamin D 3 . Rats fed the highest doses of vitamin D had significantly greater (p < 0.05) trabecular BMC, BMD, bone volume, and connectivity density, and greater midshaft total cross-sectional area, compared to rats on the vitamin D-deficient diets, with no significant difference due to vitamin D source. Vitamin D 2 -rich yeast baked into bread is bioavailable and improves bone quality in vitamin D-deficient animals. 6 Among adolescents aged 9-19 y, only 24-53% achieved the AI, 200 IU/d, from vitamin D in foods, and among adults over age 50 y, fewer than 10% achieved the AI, 400-600 IU/d, from food alone. These percentages increased somewhat when vitamin D supplements were considered, but g20% of the U.S. population still failed to meet their vitamin D requirements. With the recent increase in vitamin D requirements to 600 IU/d and 800 IU/d for those over age 70, 7 the gap widens. New food sources of vitamin D could address this gap.
' INTRODUCTION
Vitamin D is a major regulator of calcium absorption 1 and therefore a determinant of bone mineral acquisition. Emerging research also suggests that vitamin D may also play a role in risk for a number of chronic diseases. 2 Optimal vitamin D status, as measured by serum or plasma 25-hydroxyvitamin D (25OHD) levels, has not been clearly defined, but some have proposed that as many as 70% of the U.S. population may have insufficient vitamin D status. 3 Vitamin D 3 can be produced endogenously in the skin via UVB irradiation-induced conversion of 7-dehydrocholesterol. However, cutaneous synthesis of vitamin D may not be sufficient to meet vitamin D needs in populations with limited sun exposure, resulting in a dependency on dietary vitamin D. Unfortunately, few foods are naturally rich in vitamin D, and fortified foods are relatively limited 4 and often inconsistent in their vitamin D content. 5 A recent analysis of vitamin D intake from NHANES 2005-2006 data showed that most Americans did not reach the adequate intake (AI) of vitamin D from diet alone. 6 Among adolescents aged 9-19 y, only 24-53% achieved the AI, 200 IU/d, from vitamin D in foods, and among adults over age 50 y, fewer than 10% achieved the AI, 400-600 IU/d, from food alone. These percentages increased somewhat when vitamin D supplements were considered, but g20% of the U.S. population still failed to meet their vitamin D requirements. With the recent increase in vitamin D requirements to 600 IU/d and 800 IU/d for those over age 70, 7 the gap widens. New food sources of vitamin D could address this gap.
Milk is the staple food fortified with vitamin D in the United States. In the past, vitamin D content of fortified milks has often been inconsistent and below the level specified on the label, 5 with the variation partly attributed to the addition of the fortificant in local dairies without adequate quality control. Recently published data showed that consistency of fortification has improved but that 16% of sampled milks still had vitamin D levels lower than the amount on the label. 8 Furthermore, at levels of 100 international units (IU)/cup, even if Americans consumed the three cups of milk per day recommended by the dietary guidelines, 9 this source of vitamin D alone is insufficient to bring serum 25OHD values to optimal levels for most Americans. 10 Other fortified foods have even lower levels of vitamin D per serving. 4 Novel sources of vitamin D are being evaluated. Fungi, such as yeast and mushrooms, produce vitamin D2 via UVB irradiation of ergosterol, making them naturally rich sources of vitamin D. Vitamin D 2 from UV-treated mushrooms have been found to increase serum 25OHD and bone mineral density (BMD) in rats. 11 Different ratios of the five loaves were used to achieve the desired vitamin D level for each diet. All of the diets were isocaloric and contained identical percentages of protein, fat, and carbohydrate. The vitamin D content of the diets and the bread used to make the diets was analyzed by HPLC in the laboratory of Dr. Michael Holick.
14 Study Design. Rats were maintained on the vitamin D-deficient diet for 7 weeks to establish vitamin D deficiency. At the end of 7 weeks, five rats were sacrificed, and blood was collected to confirm vitamin D deficiency. The remaining rats were randomized to the eight dietary treatments (n = 10/group), which were fed for 8 additional weeks. At the end of 8 weeks on the experimental diets, all rats were euthanized by an overdose of CO 2 . Blood was collected from the dorsal aorta into heparinized vacutainers, centrifuged to separate plasma, and stored at -80°C prior to analysis. The right femur was removed and cleaned of excess tissue and wrapped in saline soaked gauze and stored at -20°C. The left femur was similarly removed, fixed in 10% neutral buffered formalin, and then stored in 70% ethanol at 4°C until analyzed.
Plasma 25OHD Measurement. Plasma 25OHD 3 and 25OHD 2 were measured by liquid chromatography mass spectrometry (IntelimmuneWest Lafayette, IN). d 6 -25OHVD 3 and d 6 -25OHVD 2 (Medical Isotopes, Pelham, NH) were used as internal standards. Rat plasma samples were spiked with the internal standards and then extraction by methyl-tert-butyl ether (MTBE). The solvent was evaporated, and the remaining residue was derivatized/reconstituted with Secosteroid Signal Enhancing Tag (SecoSET) derivatization reagents (Intelimmune, West Lafayette, IN). The derivatized samples were analyzed using multiple reaction monitoring using an Applied Biosystems MDS SCIEX 4000 QTRAP (Applied Biosystems, Carslbad, CA) interfaced with an automated Shimadzu HPLC (Shimadzu Scientific Instruments, Columbia, MD). Certified vitamin D human serum standards (NIST standard reference material 972) were also assayed as a quality control measure. The assayed concentration of 25OHD 3 and 25OHD 2 in the standard was within 2.6% and 4.5% of the NIST specified value, respectively. The limit of quantification for this method was 0.025 nmol/L for 25OHD 3 and 0.024 nmol/L for 25OHD 2 .
Bone Measurements and Mechanical Properties. Right femurs were thawed and hydrated in 0.9% saline for 36 h. Length and width at the midpoint were measured using digital Vernier calipers. Bone density was determined by underwater weighing using an analytical balance (model AG204, Mettler Toledo, Columbus, OH). Femoral breaking strength at the midshaft was assessed with a shear test using an MTS Sintech 10 (MTS, Eden Prairie, MN).
15,16
Peripheral Quantitative Computed Tomography (pQCT). Left femurs from animals fed the lowest and highest doses of vitamin D were analyzed by pQCT (Stratec Electronics). Femurs were scanned in two 1 mm slices at 18 and 50% from the distal end of the bone. The 18% site was chosen as a site that would be rich in trabecular bone while avoiding the condyles. The 50% site represents a cortical rich region. 16 Scans were performed with a 0.07 mm voxel size. Thresholds for the segmentation of trabecular and cortical bone were set at 500 mg/cm 3 and 900 mg/cm 3 . Parameters evaluated by pQCT included total, cortical, and trabecular bone mineral content (BMC), BMD, and area, cortical thickness, endosteal circumference, and periosteal circumference.
Microcomputed Tomography. The same bones that were analyzed by pQCT were also analyzed by microCT with a μCT 40 scanner (Scanco Medical, Switzerland). The trabecular bone at the distal femur was scanned at an isotropic resolution of 16 μm. The bones were scanned in 62 contiguous slices beginning at 18% from the distal end to match the pQCT measurement site and proceeded distally covering a distance of 1 mm. Trabecular bone was delimited by manually contouring the region of interest for every 10th slice and using the automated morph program to interpolate shape changes between the contoured slices. Segmentation values were sigma = 0.8 and support = 1, and a binarization threshold of 313 was visually chosen. All trabecular bone parameters were calculated using a 3D direct model. Parameters evaluated for trabecular bone included tissue volume (TV, mm 3 ), bone volume (BV, mm Cortical bone parameters were assessed at the midshaft as previously described. 16 Briefly, a total of 50 slices were acquired at a 16-μm resolution. Cortical bone was separated using a semiautomatic contour tracking algorithm to detect the outer and inner boundaries of the cortex. Parameters evaluated for cortical bone included bone volume, cortical thickness (mm), and polar moment of inertia (pMOI, mm 4 ).
Statistical Analysis. Statistical analysis was performed using SAS 9.2 (SAS Institute, Cary, NC) using two-way ANOVA. For all analyses, significance was accepted at p < 0.05.
' RESULTS Body Weight and Food Intake. There were no differences in body weight or food intake between any of the groups.
Dietary Vitamin D Content. The analyzed vitamin D contents and target values of the experimental diets are given in Table 1 . Bone Measurements. Bone length, width, density, and peak breaking strength did not differ by vitamin D dose or source (Table 2) .
Results from pQCT showed that vitamin D dose had a significant effect on trabecular BMC (p = 0.002), BMD (p = 0.004), and area (p = 0.049) at the distal femur. There was no significant effect of vitamin D source, nor an interaction of dose and source, on either of these parameters. Between rats fed the lowest and highest doses of vitamin D2 yeast, there was a 12.5% increase in trabecular BMC, a 23.1% increase in trabecular BMD, and an 8.8% increase in trabecular area. Between rats fed the lowest and highest doses of vitamin D3, there was a 1.3% increase in trabecular BMC, an 8.0% increase in trabecular BMD, and a 6.1% increase in trabecular area. Other parameters at the distal femur did not differ due to vitamin D dose or source (Table 3) . At the midshaft, we did not observe any differences in BMC, BMD, cortical thickness, or cortical area. However, vitamin D dose had a small but statistically significant effect on periosteal Journal of Agricultural and Food Chemistry ARTICLE circumference (p = 0.03), endosteal circumference (p = 0.01), and total area (p = 0.03) at the midshaft. There was no effect of vitamin D source, nor an interaction of vitamin D dose and source, on these measurements. Between rats fed the lowest and highest doses of vitamin D2 yeast, there was a 2.1% increase in periosteal circumference, a 3.8% increase in endosteal circumference, and a 4.3% increase in total area. Between rats fed the lowest and highest doses of vitamin D3, there was a 1.8% increase in periosteal circumference, a 1.8% increase in endosteal circumference, and a 3.5% increase in total area.
MicroCT analysis revealed that, at the distal site, vitamin D dose had a significant effect on trabecular bone volume (p = 0.02) and connectivity density (p = 0.03). There was no effect of vitamin D source, nor an interaction of dose and source, on either parameter. Between rats fed the lowest and highest levels of vitamin D2 yeast, there was a 26.2% increase in trabecular bone volume and a 22.6% increase in connectivity density. Between rats fed the lowest and highest levels of vitamin D3, there was a 2.7% increase in trabecular bone volume and a 3.5% increase in connectivity density. No differences were seen in trabecular number, trabecular separation, or trabecular thickness. MicroCT measurements at the midshaft were not significantly different due to vitamin D source or dose (Table 3) . Bread fortified with vitamin D3 has previously been investigated for its ability to raise vitamin D status. Elderly subjects who were given a daily serving of bread fortified with 5000 IU vitamin D 3 for one year experienced an average increase in serum 25OHD of 98 nmol/L. 17 In healthy adult women randomized to consume wheat or rye bread fortified with vitamin D 3 at a level of 400 IU/day for three weeks, serum 25OHD increased by 16.3 and 14.9 nmol/L, respectively, neither of which was significantly different than the increase from an equivalent dose of a vitamin D supplement. 18 We fed bread made with yeast containing high levels of vitamin D 2 to vitamin D-deficient rats at four doses and observed an increase in plasma 25OHD status with increasing vitamin D 2 intake. These data confirm that vitamin D 2 from bread made from UV-irradiated, vitamin D 2 -rich yeast is bioavailable and represents a potential new food source of vitamin D. In the United States, bread may be fortified with vitamin D at levels up to 90 IU/100 g, the maximum level allowed for grain products. 4 Fortifying bread at this level could provide Americans, who eat on average 79 g of bread per day, 12 with an additional 71.1 IU of vitamin D per day. If the fortification allowance for bread was increased, bread made with vitamin D 2 -rich yeast could provide even more vitamin D.
Previously, the dose-response relationship between dietary vitamin D 3 and plasma 25OHD has been described as curvilinear, with plasma 25OHD increasing rapidly at low dietary vitamin D 3 levels and approaching a plateau at higher dietary vitamin D 3 levels. 19 In rats and mice, Fleet et al. 20 found a curvilinear relationship between dietary vitamin D 3 and 25OHD with an inflection point around 200 IU/kg diet. Similarly, our data demonstrate a curvilinear relationship between vitamin D intake and plasma 25OHD for both vitamin D 3 and vitamin D 2 -rich yeast. For both vitamin D sources, we observed a steep increase in plasma 25OHD with increasing dietary vitamin D below ∼100 IU/kg diet and a more shallow increase in plasma 25OHD at higher doses. The inflection point appears to be between 100 and 200 IU/kg. Though the shape of the curve was similar for both vitamin D sources, plasma 25OHD levels achieved were lower in rats fed vitamin D 2 -rich yeast compared to that in rats fed vitamin D 3 . This difference in plasma 25OHD could represent differences in bioavailability or differences in clearance rate between the two forms.
There has been much debate as to whether vitamin D 2 and D 3 are equivalent in their ability to raise vitamin D status. Adult males given a single large dose of 50,000 IU of either vitamin D 2 or D 3 had similar initial rises in serum 25OHD. 21 However, after three days, serum 25OHD in the subjects given vitamin D 2 began to decline, while serum 25OHD remained elevated in the subjects given vitamin D 3 . Similarly, in elderly women, a single oral dose of 300,000 IU vitamin D 3 caused a greater initial rise and a slower rate of decline in serum 25OHD, compared with 23 or as fortified orange juice, 24 produced and maintained similar increases in serum 25OHD in healthy adults. Together, these data suggest that vitamin D 2 may indeed have a more rapid turnover rate in the serum than vitamin D 3 but that the difference may be inconsequential when vitamin D is given daily. Contrarily, we found that rats fed vitamin D 2 for eight weeks had lower plasma 25OHD levels than rats fed vitamin D 3 , suggesting that in growing rats, vitamin D 2 may have a lower capacity to increase and sustain plasma 25OHD levels than vitamin D 3 .
In addition to comparing the effects of vitamin D sources and doses on serum 25OHD status, it is important to also consider whether vitamin D source and dose also have a functional impact. We compared the measurements of bone strength, density, and microarchitecture as functional indicators of vitamin D status. To our knowledge, we are the first to compare the effects of dietary vitamin D 3 and D 2 on bone microarchitecture. Vitamin D is traditionally believed to influence bone quality after renal conversion to the endocrine hormone 1,25-dihyroxyvitamin D (1,25(OH) 2 D) through its role as a regulator of calcium absorption and PTH production, 1 and it may also have direct effects on bone through local conversion to 1,25(OH) 2 D within bone cells. 25 Rickets is associated with very low levels of circulating 25OHD (typically less than 20 nmol/L). 26 Fleet et al. 20 showed that mice fed a diet containing 25 IU/kg vitamin D 3 from weaning to 14 weeks of age attained borderline deficient serum 25OHD levels (25-40 nmol/L) and reduced serum 1,25-(OH) 2 D levels, and had significantly reduced femoral BMD and BMC compared to that in mice fed 1000 IU/kg vitamin D 3 . Anderson et al. 27 compared bone histomorphometric measures among rats who received daily vitamin D 3 doses ranging from 50 to 500 ng/day (approximately 100-1000 IU/kg diet) from 10 to 30 weeks of age. At the distal femur, they observed increased bone volume fraction, trabecular number, and decreased trabecular separation between rats fed 500 ng/day vitamin D 3 and rats fed 50 ng/day. We found a similar positive effect of high vitamin D intake in the growing rat on trabecular bone BMD, BMC, area, bone volume, and connectivity density at the distal femur. The effect of vitamin D dose did not differ between crystalline vitamin D 3 and vitamin D 2 -rich yeast, indicating that the two sources have equivalent ability to improve trabecular bone. We also found that higher vitamin D intake increased endosteal circumference, periosteal circumference, and total cross-sectional area of the femur midshaft. This effect did not differ due to vitamin D source, again suggesting that crystalline vitamin D 3 and vitamin D 2 -rich yeast are equivalent in their effect on cortical geometry.
There are some limitations to our work. First, we did not evaluate the bioavailability of vitamin D 2 -rich yeast in bread compared to that of crystalline vitamin D 2 . However, since many food and supplement sources of vitamin D contain vitamin D 3 , we felt that vitamin D 3 was an appropriate comparison. Also, we did not incorporate the crystalline vitamin D 3 into bread before adding it to the rat diet. Adding vitamin D 3 directly to the diet is more representative of the range of vitamin D fortified foods available on the market; however, since our vitamin D 3 diets lacked the bread matrix of the vitamin D 2 diets, we cannot be certain that any differences between the diets were due to the vitamin D form and not other components of the bread. Second, our experiment was performed in young, growing, vitamin D-deficient rats. As a result, our findings may not apply to other life stages or to vitamin D-replete individuals. Third, measuring tissue distribution of the vitamers and their metabolites would have been useful to fully assess the bioefficacy and metabolism of these two vitamin D sources.
In summary, we have demonstrated vitamin D from vitamin D 2 -rich yeast is bioavailable from bread. When bread made with this yeast was fed to growing, vitamin D-deficient rats, plasma 25OHD increased in a dose-dependent manner. Though plasma 25OHD levels were lower in rats fed bread made with vitamin D 2 -rich yeast than in rats fed vitamin D 3 , the two sources were equally effective in improving trabecular BMC, BMD, bone volume, and connectivity density, and cortical geometry. Therefore, bread made with vitamin D 2 
